Active Older Adult Program on Health and Well-being

Completed

• Conditions: Older Adult

• Registration Number: NCT04897373
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this study is to determine whether a structured 12-week program designed for older adults will improve physical function and, in parallel, circulating biomarkers of aging

Detailed Description

Not available

Study Timeline

• Study Start: 2018-08-07
• Primary Completion: 2020-04-02
• Study Completion: 2020-04-02
• Status Verified: 2021-05
• Study First Submitted: 2021-05-17
• Study First Submitted QC: 2021-05-19
• Last Update Submitted: 2021-05-19
• Study First Posted: 2021-05-21
• Last Update Posted: 2021-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Men and women age 55 years or older.
• Membership at the DAHLC.
• New to AOA (Active Older Adult) Program and commitment to full participation in the twelve-week program.
• Must be able to get down and off the floor with little assistance.

Read More

Exclusion Criteria

• Inability to provide informed consent.
• Previous participation in the AOA Program at the DAHLC.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in repeated chair rise time	Baseline to end of study, approximately 14 weeks	Chair stand test where participants will perform a chair rise movement for five repetitions. The series of 5 repetitions will be timed and measured in seconds.
Change in plasma protein levels reflective of biological age	Baseline, week 12	Blood samples will be obtained at baseline and at 12 weeks. The concentration of target proteins (pg/mL) in the plasma will be measured and compared between baseline and week 12.
Change in expression of senescence-related genes in blood cells	Baseline, week 12	Blood samples will be obtained at baseline and at 12 weeks. The expression of senescence-related genes (arbitrary units) will be measured in immune cells isolated from whole blood and compared between baseline and week 12.

Secondary Outcome Measures

Name	Time	Method
Change in Self-reported Physical Function	Baseline, week 12	Measured using the Physical Component Scale (PCS) from the 12-Item short form general health survey (SF-12).
Change in Performance-based Physical Function	Baseline, week 12	Measured using the timed up-and-go test (seconds to complete).
Change in Mental Function	Baseline, week 12	Measured using the Mental Component Scale (MCS) from the 12-Item short form general health survey (SF-12)
Change in self-assessment of well-being	Baseline, week 12	Measured using a linear analogue self-assessment scale of well-being from 0 ("as bad as it can be") to 10 ("as good as it can be") of mental, physical, emotional, and spiritual well-being, level of social activity, and overall quality of life during the past week

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States